Minnesota is currently home to 2104 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain
NCT05775510
Recruiting
Medtronic, Inc. is sponsoring the SENSE SCS clinical study, a prospective, multi-center, post-market, non-randomized, observational study with a hybrid decentralized model of execution, utilizing a mobile application for the collection of patient reported outcomes (PROs). The purpose of the study is to evaluate workflow of a mobile application for collection of PROs and to gather data on patient experience with spinal cord stimulation therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Twin Cities Pain Clinic, Edina, Minnesota
Conditions: Pain, Intractable, Pain, Chronic
Register for Updates
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566
Recruiting
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota
Conditions: Small Cell Lung Cancer (SCLC)
Register for Updates
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105
Recruiting
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota
Conditions: GIST
Register for Updates
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
NCT05723835
Recruiting
The purpose of this study is to find out if somapacitan is safe and how well somapacitan works in children either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Somapacitan is a new growth hormone medicine for treatment of low level of growth hormone. The study will last for about 3 years. During the study, the participants will be treated with somapacitan once a week. Somapacitan can be injected anytime during the day. The study doctor or nu... Read More
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
04/24/2024
Locations: Children's Minnesota, Saint Paul, Minnesota
Conditions: SGA, Turner Syndrome, Noonan Syndrome, ISS
Register for Updates
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
NCT05671835
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/24/2024
Locations: Minnesota Lung Center, Edina, Minnesota
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
NCT05670730
Recruiting
AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping. Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers. Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.
Gender:
Male
Ages:
Between 7 years and 55 years
Trial Updated:
04/24/2024
Locations: Gillette Children's, Saint Paul, Minnesota
Conditions: Duchenne Muscular Dystrophy, Exon 44
Register for Updates
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741
Recruiting
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cystic Fibrosis
Register for Updates
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862
Recruiting
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Minnesota Oncology Hematology, Saint Paul, Minnesota
Conditions: Breast Cancer
Register for Updates
Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus
NCT05591222
Recruiting
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2024
Locations: Minnesota Clinical Study Center, New Brighton, Minnesota
Conditions: Discoid Lupus Erythematosus
Register for Updates
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Recruiting
This is an international, multicenter study with two components: Registry A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection Enrollment is open to all genes on the RD Rare Gene List Natural History Study A prospective, standardized, longitudinal Natural History Study Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives Genotype Characterization Cro... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
04/24/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Register for Updates
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328
Recruiting
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Mercy Hospital, Coon Rapids, Minnesota
Conditions: Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients
NCT05546359
Recruiting
Randomized, double-blind, pediatric trial of amisulpride for prophylaxis of post operative nausea and vomiting
Gender:
All
Ages:
Between 2 months and 17 years
Trial Updated:
04/24/2024
Locations: University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota
Conditions: Nausea and Vomiting, Postoperative
Register for Updates